2Department of Surgery, İstanbul University Faculty of Medicine, İstanbul-Türkiye
3Department of Radiation Oncology, İstanbul University Institute of Oncology, İstanbul-Türkiye
4Department of Pathology, İstanbul University Faculty of Medicine, İstanbul-Türkiye DOI : 10.5505/tjo.2024.4209 OBJECTIVE
Breast cancer is the most diagnosed cancer in females. Cancer screening programs increase the detection of early-stage breast cancer. This study aimed to assess the long-term outcomes and the effect of adjuvant therapies for recurrence in stage I breast cancer patients.
METHODS
We recorded clinicopathological and treatment features of the stage I breast cancer patients and evaluated
long-term outcomes retrospectively. Kaplan-Meier analysis and Cox regression analysis were used
for recurrence and overall survival.
RESULTS
308 patients with stage I breast cancer were involved in the study. The average age was 52 (range 21-81).
The median follow-up was 99 (12-380) months. Forty-three (14%) patients were aged over 65, and 162
(52.7%) patients were postmenopausal. ER, PR, and HER2 receptor positivity were 78.9%, 60.8%, and
14.3%, respectively. Lumpectomy plus adjuvant radiotherapy was performed in 82.1% of the patients,
and mastectomy in 10.7% of the patients for primary treatment. The patients received adjuvant chemotherapy
(42.5%) and adjuvant hormonal therapy (79.9%). Recurrence (local-47.8%, metastatic-52.2%)
occurred in 23 (7.5%) patients. In multivariate Cox regression analysis, we found that primary treatment
(lumpectomy + adjuvant RT or mastectomy) (p=0.614), surgical margin status (p=0.495), adjuvant
chemotherapy (p=0.259), and adjuvant hormonal therapy (p=0.289) were not statistically significant
factors for recurrence. However, aged over 65 years (p=0.002) was statistically significant.
CONCLUSION
In this study, we showed long-term outcomes in stage I breast cancer patients. It was shown that the
primary treatment type (lumpectomy + adjuvant RT or mastectomy) was not different in terms of recurrence.
In addition, it was determined that adjuvant chemotherapy did not provide benefit for recurrence
in stage I breast cancer patients in our results. For this reason, in patients with stage I cancer, more care
should be taken in the decision of adjuvant therapy.